Compass is granted two psilocybin formulation patents, for treatment-resistant depression and major depressive disorder.
Compass is granted two psilocybin formulation patents, for treatment-resistant depression and major depressive disorder.
MindMed has been added to the FTSE Global Micro-Cap Index and the FTSE Total-Cap Index.
Numinus closes on a CAD$40.25 million bought deal financing, upsized from the original CAD$30 million offering.
Red Light Holland acquires a Netherlands distributor of psilocybin-based products.
MINDCURE adds a new tech specialist to direct the development of its iSTRYM R&D platform.
Cybin announces two new drug candidates for its R&D pipeline as its pre-clinical research deepens.
Field Trip closes on a CAD$95 million bought deal financing, nearly double the original CAD$50 million offering.
Red Light Holland imports psilocybin truffles into Canada from its Netherlands supply source.
Numinus announces a CAD$30 million bought deal financing with units priced at CAD$1.25.
MINDCURE's new COO, Tarik Lebbadi, recently led an international division of Johnson & Johnson.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now